Home/Filings/3/0000899243-21-024300
3//SEC Filing

Biomatics Capital Partners, L.P. 3

Accession 0000899243-21-024300

CIK 0001840574other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 8:07 PM ET

Size

7.5 KB

Accession

0000899243-21-024300

Insider Transaction Report

Form 3
Period: 2021-06-16
Holdings
  • Series B Preferred Stock

    Common Stock (88,653 underlying)
  • Series A Preferred Stock

    Common Stock (1,535,077 underlying)
  • Series A-2 Preferred Stock

    Common Stock (973,734 underlying)
Footnotes (2)
  • [F1]Each share of the Issuer's preferred stock is convertible into common stock on an approximately 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
  • [F2]These shares are held by Biomatics Capital Partners, LP ("Biomatics LP"). Biomatics Capital Management, L.L.C. ("Biomatics GP") is the general partner of Biomatics LP. Julie Sunderland and Boris Nikolic ( the "Managing Members") are the managing members of Biomatics GP. Each of the Managing Members may be deemed to share voting and dispositive power over these shares. Each of the Managing Members and Biomatics GP disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Issuer

Verve Therapeutics, Inc.

CIK 0001840574

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001672431

Filing Metadata

Form type
3
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 8:07 PM ET
Size
7.5 KB